|
|
Post by lakers on Nov 11, 2015 20:33:52 GMT -5
What deal structure would you like to see for a new TS partnership?
Please provide one answer if you were Mgmt, another one if you were the partner(s), and a proposed compromise given our balance sheet.
As a bonus, any specific input for Pain, Migraine, PAH (API specific).
Only serious reply please. The sooner the better. Thanks.
|
|
|
|
Post by lakers on Nov 11, 2015 20:22:07 GMT -5
4:14 pm Mannkind confirms its shares will begin trading on indexes within the Tel Aviv Stock Exchange on November 15, 2015; re-confirms expectation for a direct offering to investment funds (MNKD) : Co re-affirmed its expectation of completing a registered direct offering of its common stock to selected investment funds in Israel that are required to hold securities included within certain stock indexes of the TASE. finance.yahoo.com/news/inplay-briefing-com-055139997.html#mnkd |
|
|
|
Post by lakers on Nov 11, 2015 18:52:46 GMT -5
If the TASE was true, MannKind would have filed with the SEC. I immediately smelled a rat and did not sell. Thankfully my nose did not let me down. Amen. Material event. Now, did you buy provided you had the powder? If having ammo and yes, brilliant. Chris did. |
|
|
|
Post by lakers on Nov 11, 2015 18:02:38 GMT -5
cfield, it was a gutsy post. I have respect for you. It takes a courageous man to do what you just did. I wish I posted earlier. The upshot is the crisis taught mgmt to always plan for worst case, not best. It hardened their resolve and gave them a sense of urgency to expedite ...
|
|
|
|
Post by lakers on Nov 11, 2015 16:16:20 GMT -5
finance.yahoo.com/news/mannkind-confirms-planned-stock-sale-211150487.htmlI deliver on my promise. Yours ? VALENCIA, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD.TA) (MNKD.TA) today announced that its shares will enter the following Tel Aviv Stock Exchange, or TASE, indexes as planned on November 15, 2015: TA-100, TA-75, TA-Composite, TA-Biomed, TA-Blue-Tech and TA-Tech-Elite. The Company is reconfirming its expectation of completing a previously-announced registered direct offering of its common stock to selected investment funds in Israel that are required to hold securities included within certain stock indexes of the TASE. The final number of shares to be sold in the offering will be determined based upon the number of shares the purchasers are required to hold within the indexes, and subject to the purchasers' desired allocation amounts. The shares will be issued pursuant to the Company's effective registration statement on Form S-3 (File No. 333-333-206778) and are being offered pursuant to a related prospectus supplement filed with the Securities Exchange Commission on November 9, 2015. Copies of the prospectus supplement and accompanying prospectus are available on the SEC's website located at www.sec.gov and may also be obtained by contacting the Company at 25134 Rye Canyon Loop, Suite 300, Valencia, CA 91355, Attn: Investor Relations, or by telephone at (661) 775-5300. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. The shares sold in the offering will trade on the Nasdaq Global Market as well as the TASE. According to the Israeli Securities Authority's announcement to the Company on November 11, 2015, certain restrictions will apply to the issued shares on TASE under the Israeli Securities Authority. Trading Regulations The Company's shares will continue to be listed on the Nasdaq Global Market, subject to the rules and regulations of the Nasdaq Global Market applicable to listed companies. Under Israel's Dual Listing Law, U.S.-listed companies may also list on the TASE without substantial additional regulatory requirements. Investors should note that trading on the TASE occurs Sunday through Thursday from 8:30 am to 4:30 pm Israel time, except on TASE trading holidays, and trading on the Nasdaq Global Market occurs Monday through Friday, 9:30 am to 4:00 pm Eastern Time, except on Nasdaq holidays. The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. Exchange.
|
|
|
|
Post by lakers on Nov 11, 2015 15:49:43 GMT -5
Spoke with Roberta at MNKD Her message is..... ( all she is permitted to say) They are aware of the rumors and something is being prepared by Matt. I would assume that it needs to be appropriate to the situation on hand. That is: the state of the TASA filing an the rumors being propagated by AF and like. I hope it will be a substantive reply. We stockholders need some answers. In essence she said all she could. When I asked if the press release would happen this trading session, she could'nt say. Yes, I was surprised to have my call returned but I would be reassured by a forceful and substantive response from mnkd. By utupua4 finance.yahoo.com/mbview/threadview/?&bn=0243242e-59fb-3abc-8d27-962c7bf26a1d&tid=1447272005907-78344a23-b459-48e5-bb3a-719046ce3633&tls=la%2Cd%2C14%2C3 |
|
|
|
Post by lakers on Nov 11, 2015 13:33:05 GMT -5
I believe MNKD will issue a press release. Eom.
|
|
|
|
Post by lakers on Nov 11, 2015 13:25:15 GMT -5
It is appearing like the deal will go ahead and TASE ETFs (whoever participate) will pay 97% of MNKD closing price on TASE on Nov. 12. The confusion seems to be with the 'locked up for 6 months' restriction that the ISA was having problem with, and Matt alluded to in his email to Bloomberg. So it seems that the ETFs can't sell the shares for 6 months on the TASE, but can sell those shares in NYSE or Germany. However, they can't lend the shares out...It was strange to me, at first, about these ETFs can't sell the shares since ETF in its nature is supposed to minim the sector the fund is in, so now it's clear what the problems were and how they are going solve it.
From YMB
|
|
|
|
Post by lakers on Nov 11, 2015 2:56:18 GMT -5
Inhaled Insulin Eyed As a Dementia Treatment the Psychiatry Advisor take: Insulin delivered through the nasal cavity may improve memory in those suffering from dementia. William Banks, MD a professor of internal medicine and geriatrics at the University of Washington School of Medicine and a physician at the Veteran’s Administration Puget Sound Medical Center, and colleagues made the discovery based on a mouse model. In an object recognition test, which depends a mouse's natural curiosity for new things, old mice do not remember whether objects they are presented to play with are new or old. But, after a single dose of intranasal insulin, they can remember which objects they have seen before, the researchers reported in the Journal of Alzheimer’s Disease. Although hundreds of trials are being conducted on Alzheimer’s, few are looking at insulin and how it affects cognition. Banks said there are probably 100 intranasal compounds that could be tested for treating Alzheimer’s. “Before this study, there was very little evidence of how insulin gets into the brain and where it goes,” Banks said in a statement. “We showed that insulin goes to areas where we hoped it would go.” Researchers at the UW Medicine, Veteran's Administration Puget Sound and Saint Louis University have made a promising discovery that insulin delivered high up in the nasal cavity goes to affected areas of brain with lasting results in improving memory. The findings were published online July 30 in the Journal of Alzheimer's Disease. Importantly, researchers also found that insulin does not go into the bloodstream when delivered intranasally, a major concern in the medical community because it would lower blood sugar levels. Additionally, repeated doses increased insulin's efficacy in aiding memory. www.psychiatryadvisor.com/alzheimers-disease-and-dementia/inhaled-insulin-improves-memory-dementia-treatment/article/430731/ |
|
|
|
Post by lakers on Nov 11, 2015 2:31:47 GMT -5
|
|
|
|
Post by lakers on Nov 10, 2015 22:13:02 GMT -5
FAQ & Policies to Buy Prescription Drugs Online - www.israelpharm.com/faq/IsraelPharm.com www.israelpharm.com › faq Why do some of the Israeli drugs I ordered look different than those from the U.S. ? ... What prescriptions does IsraelPharm accept? ... All medications are certified by the Israeli Ministry of Health, and most are certified by the FDA as well. Do I need a prescription to buy prescription drugs online from IsraelPharm? Yes. By law, a valid prescription is required. Without a legal prescription from your American physician, we cannot send your order. The prescription must be faxed (toll-free 1-866-544-8993) or emailed (rx@israelpharm.com) to us in its original form with no changes. How safe are the drugs from Israel? The Israel Ministry of Health uses the most stringent regulations for the quality control of all name brand and generic drugs through the strict enforcement of the internationally recognized Good Manufacturing Practice (GMP) guidelines. All medications are certified by the Israeli Ministry of Health, and most are certified by the FDA as well. Are Israeli drugs cheaper than American drugs? Drugs sold in Israel cost up to 70 percent less than drugs sold in the United States. Americans generally save 50 percent on drug bills when they shop at IsraelPharm. The Ministry of Health in Israel limits the price for which drug companies can sell their medications, and this is the saving that we pass on to you. Why are drugs less expensive at IsraelPharm than in the U.S.? In Israel, pharmacy prices are lower because the government controls the prices to keep pharmaceutical products affordable. The United States is the only developed country in the world with no similar price controls, and pharmaceutical companies can set prices for their own products, which invariably ends up more favorable to the company than to the consumer. Back to top... Are there any hidden charges? There are no hidden taxes, fees, or surcharges through our internet pharmacy! The only charges you will experience are the cost of your drugs, as listed on our website, and a $20.00 per package shipping charge. Note: American Express payments will incur a 2-percent surcharge. |
|
|
|
Post by lakers on Nov 10, 2015 20:01:01 GMT -5
|
|
|
|
Post by lakers on Nov 10, 2015 19:15:59 GMT -5
That's not quite what has been stated by management. They stated that going with API that are already FDA-approved is the quickest, lowest-cost way to market. Partnering with a BP for developing a novel drug would take the longest & be the most costly. They (Hakan/Matt) did not say that partnering with a BP to develop an existing FDA-approved API (or a generic) is not desirable. In fact, Hakan said just the opposite today. They have begun talks with potential development and/or financial partners for the API list that they simply cannot afford to develop on their own at this time. At Aegis Capital, 10/8/15 : Looking at drugs which take advantage of TS features besides just eliminating the injection. Not practical to develop new chemical entities so working for next product to be a known drug. Occasionally look at NCE’s which are nice to look at but it would be a 10 year process. 10:00 Spent a lot of time and money on the consulting process to select 2 new applications / drug candidates. First indication would be pulmonary hypertension. This is a serious effort on the company’s behalf. The R&D activities are fully staffed and preclinical work has been/is being done. We can look forward to hearing more news about this soon but not at the moment. Licensing tech to other companies - have to be careful not create competitors to ourselves. |
|
|
|
Post by lakers on Nov 10, 2015 19:07:58 GMT -5
|
|
|
|
Post by lakers on Nov 10, 2015 18:24:01 GMT -5
November 10, 2015, 11:02 A.M. ET MannKind: Buying Time…But It’s Still All About Afrezza blogs.barrons.com/stockstowatchtoday/2015/11/10/mannkind-buying-time-but-its-still-all-about-afrezza/By Ben Levisohn Shares of MannKind (MNKD) are tumbling today after the struggling biotech company announced that it would be selling up to 50 million shares by listing on the Tel Avive Stock excnage. RBC’s Adnan Butt contends that MannKind is “buying time with innovative financing [but] demand trend still matters.” He explains: Investors had been focused on when and how MannKind would raise additional capital to fund operations, along with Afrezza trajectory. MannKind disclosed the potential to sell up to 50M shares with its Tel Aviv Stock Exchange listing.Fundamentally, Afrezza ramp is still paramount where visibility from Sanofi (SNY) is listed as that is what will determine the ultimate upside or downside scenario in MannKind shares…. MannKind’s stock purchase agreements could lead to 50M shares of common stock being sold to selected investment funds in Israel and raising ~$120M+ assuming Monday’s closing price. While this could address the financing overhang for the time being, ultimately Afrezza needs to grow to ensure MannKind’s viability as expenses will continue to mount and debts will still need repayment. With ~$30M available from the Al Mann facility, ~$38M from the ATM, and potential 50M in shares offered, the pro forma total could be enough to fund operations into2017. The Street’s Adam Feuerstein explains why going to Israel was a “wise move” for MannKind: As disclosed Monday night, MannKind will sell “up to” 50 million shares of its common stock directly to Israeli-managed index funds. These exchange-traded funds are required to buy MannKind shares because the stock is now dual listed on the Tel Aviv Stock Exchange (TASE).) Instead of buying MannKind shares on the open market, MannKind offered to sell stock to the TASE ETF funds directly from the company’s treasury at a 3% discount. The amount of money raised in this offering isn’t known yet but will hinge on MannKind’s weighting in the various TASE indices, which then dictates how many shares the Israeli ETF funds need to acquire. As anyone spying a stock chart lately knows, MannKind wasn’t finding demand for its falling shares from U.S. investors, so dual-listing on the TASE and raising money from “forced” buyers in the Israeli investment community is a heads-up survival move. Shares of MannKind have tumbled 12% to $2.31 at 10:55 a.m. today, while Sanofi has declined 1.4% to $44.80. |
|
